Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies announced that the U.S. Food and Drug Administration (FDA) approved the TECNIS EyhanceTM and TECNIS EyhanceTM Toric II intraocular lens (IOL) for the treatment of cataract patients in the United States.
With this approval and subsequent commercial launch, ophthalmologists in the U.S. now have the ability to choose this next generation monofocal as the lens of choice for their patients with or without astigmatism. The first implantation of Tecnis Eyhance IOL in the US will happen in Texas next week.
More than 90% of people develop cataracts—the clouding and yellowing of the lens in the eye—by the age of 65. While part of the normal aging of the eye, left untreated, cataracts cause vision to deteriorate over time.
In fact, cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes. Cataract surgery is one of the most common outpatient procedures performed today and has a success rate of approximately 98%.
Today, cataract treatments can also offer patients vision correction, reducing or eliminating the need for glasses, in addition to removing the cataract.
“Eighty-four percent of surgeons choose monofocal IOLs for their cataract patients, so it’s thrilling to see the first breakthrough in monofocal technology in decades enter the market to add to our treatment portfolio,” Douglas Koch, MD, Houston, Texas, said in a company news release.
“It’s the first monofocal designed to provide a slight increase in the depth of focus, which is something I need for the patients in my practice looking for more from a monofocal.”
The latest innovation in the Tecnis family of IOLs—Tecnis Eyhance and Tecnis Eyhance Toric II IOLs—are defining the future of monofocals, with a breakthrough refractive surface designed to:
“Built on the proven Tecnis platform, Tecnis Eyhance combines low-light performance with breakthrough refractive surface design, providing a new kind of monofocal experience for cataract patients,” Rajesh K. Rajpal, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision, said in the news release. “Additionally, the Tecnis Eyhance Toric II lens is engineered with a new squared and frosted haptic design for added friction inside the capsular bag to treat cataract patients with astigmatism.”
The Tecnis Eyhance IOL is the latest lens in the Tecnis family, which celebrates its 20th anniversary this year. The Tecnis family portfolio is the broadest mix of IOLs for cataract patients in need of monofocals, multifocals, extended depth of focus (EDOF), and those with or without astigmatism, according to J&J Vision.
“We consistently engage with our surgeons and their patients to better understand their unmet needs, and their feedback drove us to innovate and push the boundaries of the monofocal category – a category that’s largely been stagnant for the last 20 years,” said Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision. “Tecnis Eyhance IOL is built on the foundation of our proven Tecnis platform, designed to deliver more.”
Tecnis Eyhance first launched in Europe in February 2019 and became commercially available in Latin America and Canada in the summer of 2020. Tecnis Eyhance and Tecnis Eyhance Toric II are now commercially available in the U.S., with Tecnis Eyhance Toric II launching in Europe and Canada later this year.